Table 2.
Baseline characteristics of a 4:1 matched cohort (age, sex, DM, and cumulative duration) of ranitidine and famotidine users.
| Characteristics | Ranitidine (n = 40,488) | Famotidine (n = 10,122) | p-Value |
|---|---|---|---|
| Male (n, %) | 21,208 (52.4) | 5302 (52.4) | >0.999 |
| Age (years, mean ± SD) | 59.9 ± 11.8 | 59.8 ± 11.8 | 0.765 |
| 30–49 (years, n, %) | 7836 (19.3) | 1959 (19.3) | |
| 50–59 (years, n, %) | 11,240 (27.8) | 2810 (27.8) | |
| 60–69 (years, n, %) | 11,400 (28.2) | 2850 (28.2) | |
| 70–79 (years, n, %) | 10,012 (24.7) | 2503 (24.7) | |
| Diabetes mellitus | 13,976 (34.5) | 3494 (34.5) | >0.999 |
| Diabetes mellitus period | >0.999 | ||
| ≤3 years | 4020 (9.9) | 1005 (9.9) | |
| ≥4 years | 9956 (24.6) | 2489 (24.6) | |
| Dosage | |||
| mg, mean ± SD) | 220,395 ± 112,850 | 29578 ± 15549 | |
| DDD (mean ± SD) | 734.6 ± 376.2 | 739.4 ± 388.7 | 0.254 |
| Cumulative duration | >0.999 | ||
| 12–17 months | 16,092 (39.8) | 4023 (39.8) | |
| 18–23 months | 8524 (21.0) | 2131 (21.0) | |
| 24–29 months | 5440 (13.4) | 1360 (13.4) | |
| ≥30 months | 10,432 (25.8) | 2608 (25.8) |
DDD, Defined daily dose.